Crossmark

Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

Crossref DOI link: https://doi.org/10.1007/s00280-018-3641-5

Published Online: 2018-07-16

Published Print: 2018-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Patnaik, Amita

Gordon, Michael

Tsai, Frank

Papadopoulos, Kyriakos P. https://orcid.org/0000-0002-0667-2620
Rasco, Drew

Beeram, Muralidhar

Fu, Siqing

Janku, Filip https://orcid.org/0000-0002-8123-4065
Hynes, Scott M.

Gundala, Sushma R. https://orcid.org/0000-0001-6545-7763
Willard, Melinda D.

Zhang, Wei

Lin, Aimee Bence

Hong, David https://orcid.org/0000-0001-8721-1609
License Information

Text and Data Mining valid from 2018-07-16
More Information

Article History

First Online: 16 July 2018